We are live on ! Find out more
BNR icon

Burning Rock Biotech

19 hedge funds and large institutions have $18.7M invested in Burning Rock Biotech in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 8 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.68% less ownership

Funds ownership: 20.22% → 19.54% (-0.68%)

32% less funds holding

Funds holding: 28 → 19 (-9)

75% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 8

78% less capital inflows, than outflows

Capital inflows: $190K | Capital outflows: $862K

82% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 11

Holders
19
Holders Change
-9
Holders Change %
-32.14%
% of All Funds
0.28%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
2
Increased
2
Reduced
8
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

BNR Hedge Fund Activity: Q4 2023 in Review

19 of the 6,880 institutional investors tracked by Wall St. Rank reported a position in Burning Rock Biotech (BNR) for Q4 2023, worth a combined $18.7M — down 7.2% from $20.1M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of BNR and 2 opened new positions — a net loss of 9 holders — while 8 trimmed existing stakes and 2 added.

The largest buyer was Kynam Capital Management, adding an estimated $179K. The largest seller was Barclays, exiting entirely with an estimated $252K sold.

  • 19 institutional investors held Burning Rock Biotech (BNR) as of Q4 2023, down from 28 in Q3 2023.
  • Funds reported $18.7M of Burning Rock Biotech stock for Q4 2023, down 7.2% quarter-over-quarter.
  • 2 funds opened new Burning Rock Biotech positions in Q4 2023 and 11 closed out, a net change of -9 holders.
  • The largest Burning Rock Biotech buyer in Q4 2023 was Kynam Capital Management, an estimated $179K added.
  • The largest Burning Rock Biotech seller in Q4 2023 was Barclays, an estimated $252K sold.

Based on aggregated 13F filings for Q4 2023.